Sintilimab plus chemo for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two medicines (sintilimab and FOLFIRI) as a second option for people with advanced stomach cancer that no longer responds to first treatment. It aims to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced stomach cancer (that has spread or can't be removed with surgery) and it's HER2-negative.
- You have already tried one type of cancer treatment and it stopped working or you had bad side effects.
- You are at least 18 years old and are generally able to care for yourself (ECOG score 0-2).
- Your blood counts and liver/kidney function must be good enough, based on standard lab tests.
- You are not pregnant or breastfeeding, and if you can have children, you agree to use birth control during and for 3 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
This trial tests a combination of two drugs – a new form of irinotecan (liposomal irinotecan) and an immunotherapy drug called sintilimab – for people with stomach cancer that has progressed after initial treatment. The goal is to see if this combination can work as a second-line option.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiotherapy can help people aged 75 or older with locally advanced stomach cancer. It aims to shrink tumors and improve outcomes.
This trial tests whether adding the immunotherapy drug Sintilimab to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It's for people with high-risk or advanced stage cancer that has a specific genetic feature (dMMR or MSI-H).
This clinical trial is testing a combination of three drugs—sintilimab, fruquintinib, and standard chemotherapy—as a first treatment for advanced stomach cancer that cannot be surgically removed. The goal is to see if this combination can shrink the cancer enough to allow surgery, potentially improving outcomes.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
Hear when a new Unresectable/Metastatic Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.